Skip to main content

Sequenom Stock Slips 5.21 Percent on Q2 Earnings

NEW YORK, Aug. 9 (GenomeWeb News) - Shares in Sequenom were down 5.21 percent, or $.05, at $.91 in mid-afternoon trading after the company yesterday reported a slight increase in second-quarter revenues as losses slid sharply on lower costs.

 

As GenomeWeb News reported last night, Sequenom posted a rise in second-quarter revenues to $6.2 million, versus $6 million in the year-ago quarter, an increase the company attributed to both the addition of new customers and the upgrading of the firm's analysis systems by existing customers.

 

Sequenom's research and development spending dropped to about $3 million in the quarter from $5.7 million a year earlier.

 

The company posted a net loss of $6 million, or $.15 per share, versus a year-ago loss of $9.8 million, or $.25 per share.

As of June 30, Sequenom had cash, cash equivalents, short-term investments, and restricted cash totaling $25.4 million.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.